HCD122

DRUG4 trials

Sponsors

Novartis Pharmaceuticals

Conditions

Chronic Lymphocytic LeukemiaFollicular LymphomaHodgkin's LymphomaMultiple MyelomaNon-Hodgkin's Lymphoma

Phase 1

Dose-finding Trial of HCD122 in Patients With Chronic Lymphocytic Leukemia (CLL) That is Relapsed or Non-responsive to Prior Fludaribine Therapy

TerminatedNCT00108108

Novartis PharmaceuticalsChronic Lymphocytic Leukemia

Start: 2005-04-30End: 2008-06-30Updated: 2012-10-01

Safety, Efficacy, Dose-finding Study of a Monoclonal Antibody in Patients With Multiple Myeloma

CompletedNCT00231166

Novartis PharmaceuticalsMultiple Myeloma

Start: 2005-09-30End: 2009-05-31Updated: 2018-10-11

Study of HCD122 in Adults With Non-Hodgkin's or Hodgkin's Lymphoma Who Have Progressed After at Least Two Prior Therapies

CompletedNCT00670592

Novartis PharmaceuticalsHodgkin's Lymphoma, Non-Hodgkin's Lymphoma

Start: 2008-03-31End: 2013-02-28Updated: 2020-12-17

Study of HCD122 (Lucatumumab) and Bendamustine Combination Therapy in CD40+ Rituximab-refractory Follicular Lymphoma

CompletedNCT01275209

Novartis PharmaceuticalsFollicular Lymphoma

Start: 2011-02-28End: 2012-05-31Updated: 2020-12-08